OncoSil (ASX:OSL) puts a A$98m revenue number on a A$43m market cap
1 Articles
1 Articles
OncoSil (ASX:OSL) puts a A$98m revenue number on a A$43m market cap
A 70% gross margin at scale reframes how the Macquarie Park manufacturing build should be valued OncoSil Medical (ASX:OSL) has dropped its mid-July investor presentation, and for a company that spent years being a regulatory story, this deck reads like a commercial one. The headline number is a A$98 million revenue opportunity from the new Sydney manufacturing facility at roughly 70% gross margin at full capacity. Against a A$43 million market c…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
